![t dm1 side effects t dm1 side effects](https://tpucdn.com/review/dream-machines-dm1-fps/images/dm1fps_sw5_small.jpg)
The 12 cycles cut-off was chosen based on the EMILIA trial median PFS (9.6 months), to identify a patient population treated with T-DM1 for longer time. Methods: HER2 positive MBC pts who had received ≥12 cycles of T-DM1 across 18 Italian cancer centers were enrolled from January 2017 to September 2018. The aim of this study was to evaluate the safety profile of T-DM1 when delivered for ≥12 cycles. However, little is known about its long term toxicity. Pascale" -Breast Oncology Unit, Naples, Italy Department of Oncology, University Hospital of Udine, Udine, Italy School of Medical Oncology, Department of Medicine, University of Udine, Udine, Italy Oncology Unit, Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy Medical Oncology, Mauriziano Hospital Department of Oncology, University of Turin, Torino, Italyīackground: T-DM1 is widely used in HER2 positive metastatic breast cancer (MBC) patients (pts), often for many cycles until progression. Pascale" -Breast Oncology Division, Naples, Italy Istituto Nazionale Tumori IRCCS "Fondazione G. Croce and Carle Teaching Hospital, Cuneo, Italy Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy Istituto Nazionale Tumori IRCCS "Fondazione G. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy Department of Oncology, ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy Oncology Day Hospital Unit, IRCCS CROB, Rionero in Vulture, Italy Breast Unit Cardarelli Hospital, Naples, Italy Investigational and Clinical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy Phase 1 Research Unit, ASST Monza, Monza, Italy Breast Unit Medical Oncology S. Department of Clinical Medicine and Surgery, Oncology Division, University Federico II, Naples, Italy Division of Medical Oncology, “Regina Elena” National Cancer Institute, Rome, Italy Department of Medical Oncology, IRCCS AOU San Martino–IST, National Cancer Institute, Genova, Italy S.